Cargando…

Parenteral Sustained Release Lipid Phase-Transition System of Ziprasidone: Fabrication and Evaluation for Schizophrenia Therapy

INTRODUCTION: Ziprasidone (ZP) is a novel atypical antipsychotic agent effective in the treatment of positive and negative symptoms of schizophrenia with low chances for extrapyramidal side effects (EPs) and cognitive deficits. ZP possesses poor oral bioavailability (~50%), short biological half-lif...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khan, Urooj A, Parveen, Uzma, Hasan, Nazeer, Ahmed, Mohammad Zubair, Saad, Suma, Ahmad, Farhan J, Jain, Gaurav K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7294276/ https://www.ncbi.nlm.nih.gov/pubmed/32606594 http://dx.doi.org/10.2147/DDDT.S247196

Ejemplares similares

Ziprasidone Hydrocloride: What Role in the Management of Schizophrenia?
por: Mattei, Chiara, et al.
Publicado: (2011)

Natural gums as sustained release carriers: development of gastroretentive drug delivery system of ziprasidone HCl
por: AJ, Rajamma, et al.
Publicado: (2012)

The Effectiveness of Cross-Tapering Switching to Ziprasidone in Patients with Schizophrenia or Schizoaffective Disorder
por: Ko, Young-Hoon, et al.
Publicado: (2014)

Efficacy and Metabolic Influence on Blood-Glucose and Serum Lipid of Ziprasidone in the Treatment of Elderly Patients with First-Episode Schizophrenia
Publicado: (2017)

Ziprasidone in the Treatment of Delusional Parasitosis
por: Contreras-Ferrer, P., et al.
Publicado: (2012)

Comparison of Efficacy and Safety Between Low-Dose Ziprasidone in Combination With Sertraline and Ziprasidone Monotherapy for Treatment-Resistant Patients With Acute Exacerbation Schizophrenia: A Randomized Controlled Trial
por: Shi, Hui, et al.
Publicado: (2022)

Double-blind comparison of ziprasidone and risperidone in the treatment of Chinese patients with acute exacerbation of schizophrenia
por: Zhang, Hongyan, et al.
Publicado: (2011)

PM395. The Effectiveness of Cross-Tapering Switching to Ziprasidone in Patients with Schizophrenia or Schizoaffective Disorder
por: Na, Kyoungsae, et al.
Publicado: (2016)

Ziprasidone in the treatment of mania in bipolar disorder
por: Nicolson, Stephen E, et al.
Publicado: (2007)

Ziprasidone Associated Neuroleptic Malignant Syndrome
por: Bell, Jeffrey D., et al.
Publicado: (2021)

Literature review and economic evaluation of oral and intramuscular ziprasidone treatment among patients with schizophrenia in China
por: Yeh, Yu-Chen, et al.
Publicado: (2019)

An Inter-Ethnic Comparison Study of Ziprasidone Plasma Levels, Dosage and Clinical Response in Patients with Schizophrenia
por: Lv, Dongsheng, et al.
Publicado: (2017)

Polyphenols from Berries of Aronia melanocarpa Reduce the Plasma Lipid Peroxidation Induced by Ziprasidone
por: Dietrich-Muszalska, Anna, et al.
Publicado: (2014)

Expert Canadian consensus suggestions on the rational, clinical use of ziprasidone in the treatment of schizophrenia and related psychotic disorders
por: Kutcher, Stan, et al.
Publicado: (2005)

Clinical Practice Associated with a Switch from and to Ziprasidone during Routine Inpatient Treatment of Patients with Schizophrenia
por: Müller, Matthias J.
Publicado: (2011)

A Case Report of Priapism Caused by Ziprasidon
por: Karamustafalioglu, Nesrin, et al.
Publicado: (2013)

MON-675 Ziprasidone Induced Diabetic Ketoacidosis
por: Thanikonda, Varshitha, et al.
Publicado: (2020)

Evaluation of intramuscular olanzapine and ziprasidone in the medically ill
por: Patel, Seema M., et al.
Publicado: (2021)

Evaluation of Brain Targeting and Antipsychotic Activity of Nasally Administrated Ziprasidone Lipid–Polymer Hybrid Nanocarriers
por: Abo El-Enin, Hadel A., et al.
Publicado: (2023)

Evidence review and clinical guidance for the use of ziprasidone in Canada
por: Gardner, David M, et al.
Publicado: (2013)

Case Report: Ziprasidone induced neuroleptic malignant syndrome
por: Sedhai, Yub Raj, et al.
Publicado: (2021)

Preparation, Characterization and in vivo Evaluation of Parenteral Sustained Release Microsphere Formulation of Zopiclone
por: Swapna, N, et al.
Publicado: (2010)

Ziprasidone, haloperidol and clonazepam intramuscular administration in the treatment of agitation symptoms in Chinese patients with schizophrenia: A network meta-analysis
por: Su, Liang, et al.
Publicado: (2018)

Parenteral Nutrition and Lipids
por: Raman, Maitreyi, et al.
Publicado: (2017)

Nonisothermal Kinetics Analysis of the Dehydration of Ziprasidone Hydrochloride Monohydrate by Thermogravimetry
por: Ravikiran, A., et al.
Publicado: (2013)

Emerging treatment options in bipolar disorder in adolescents: focus on ziprasidone
por: Khan, Afshan A, et al.
Publicado: (2010)

Ziprasidone as Adjunctive Therapy in Severe Bipolar Patients Treated with Clozapine
por: Bartolommei, Natalia, et al.
Publicado: (2014)

Failed efficacy of ziprasidone in the treatment of post-traumatic stress disorder
por: Ramaswamy, Sriram, et al.
Publicado: (2015)

Efficacy of Ziprasidone in Controlling Agitation during Post-Traumatic Amnesia
por: Noé, Enrique, et al.
Publicado: (2007)

Human Hemoglobin and Antipsychotics Clozapine, Ziprasidone and Sertindole: Friends or Foes?
por: Platanić Arizanović, Lena, et al.
Publicado: (2023)

The safety and efficacy of sequential intramuscular/oral ziprasidone treatment of acute episode in patients with schizophrenia: a multicenter, open-labeled study
por: Wu, Yaxue, et al.
Publicado: (2023)

Intranasal Cerium Oxide Nanoparticles Ameliorate Cognitive Function in Rats with Alzheimer’s via Anti-Oxidative Pathway
por: Danish, Syed Mohammad, et al.
Publicado: (2022)

Fabrication and characterization of electrospun nanofibers using biocompatible polymers for the sustained release of venlafaxine
por: Hashem, Heba M., et al.
Publicado: (2022)

Ziprasidone and its Association with Sudden Cardiac Death - A Case Report
por: Sidana, Ajeet, et al.
Publicado: (2004)

Behavioral and Metabolic Effects of the Atypical Antipsychotic Ziprasidone on the Nematode Caenorhabditis elegans
por: Gubert, Priscila, et al.
Publicado: (2013)

A Systematic Review and Case Series of Ziprasidone for Psychosis in Parkinson’s Disease
por: Younce, John R., et al.
Publicado: (2019)

Ziprasidone-Induced Oculogyric Crisis in a 74-Year-Old Female
por: Wilson, Alphonso, et al.
Publicado: (2020)

Restless legs syndrome following the use of ziprasidone: a case report
por: Zhu, Cuizhen, et al.
Publicado: (2020)

Medication adherence and utilization in patients with schizophrenia or bipolar disorder receiving aripiprazole, quetiapine, or ziprasidone at hospital discharge: A retrospective cohort study
por: Berger, Ariel, et al.
Publicado: (2012)

Nano Matrix Soft Confectionary for Oral Supplementation of Vitamin D: Stability and Sensory Analysis
por: Ahmed, Mohammad Zubair, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7vjb447vi0e49r7gskm2ii6d3i